BioAtla, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Collaboration and other revenue was $2.0 million for the fourth quarter and full year 2025, net income Net loss for the fourth quarter of 2025 was $9.8 million, compared to a net loss of $14.9 million for the same period in.
“BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights – Initiated a formal process to monetize assets – Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 – BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights.”
Restructurings & Charges
BioAtla, Inc. announced a restructuring with charges of between $0.5 and $0.6 million affecting the Company (approximately 70%).
“formal process to explore and evaluate strategic options to maximize shareholder value. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs. The Company expects to pay for the majority of these costs in the first quarter of 2026. The estimates of the”
Listing & Compliance Notices
BioAtla, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna”
Listing & Compliance Notices
BioAtla, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna”
Governance Changes
BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).
“On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).”
Governance Changes
BioAtla, Inc.: Filed Certificate of Designation for Series A Junior Preferred Stock (Super-Voting Share) establishing its voting, dividend, liquidation, redemption, and transfer terms (effective 2026-01-09).
“On January 9, 2026, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.”
Material Agreements
BioAtla, Inc. entered into Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. valued at aggregate $40 million (effective 2025-12-30).
“On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”).”
Listing & Compliance Notices
BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance wi”
Earnings Releases
BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.”
Governance Changes
BioAtla, Inc.: Amended advance notice provisions for stockholder nominations and proposals, removing certain disclosure and interview requirements, clarifying cure periods and disclosure of financial supporters, and modifying definitions (effective 2024-04-22).
“On April 22, 2024, the board of directors (the “Board”) of BioAtla, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Bylaws”), which became immediately effective, and include, among other things, the following changes in Article I, Section 2 relating to advance notice requirements applicable to stockholder-submitted nominations and other business proposals (the “Advance Notice Bylaw”): • remove the requirement for a Proposing Person (as defined in the Advance Notice Bylaw) to disclose any knowledge that another person or entity is Acting in Concert (as defined in the Advance Notice Bylaw) in describing the material terms of any agreement, arrangement or understanding entered into for the purpose of acquiring, holding, disposing or voting shares of the Company’s stock; • clarify that a stockholder’s notice required by the Advance Notice Bylaw must disclose the names, addresses and Company stock ownership of record”
Earnings Releases
BioAtla, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“BioAtla, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.